- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Bowel cancer

Australia has one of the highest rates of bowel cancer in the world. Each year, more than 16,000 Australians are diagnosed with bowel cancer. Many bowel cancers are detected at later, difficult to treat stages. If detected early, almost all cases of bowel cancer are curable. We are working to develop better early detection tests and to improve treatments for bowel cancer.

Understanding how these crypts and buds develop could help scientists understand what happens
when bowel cancer develops.
Our bowel cancer research
Our bowel cancer scientists and clinicians are working to improve the detection and treatment of bowel cancer by:
- Understanding the changes in healthy bowel cells that drive cancer formation.
- Deciphering how cancer cells 'communicate' with their environment to promote tumour growth.
- The role of bacterial infections and inflammation in cancer development.
- Developing better ways to detect and treat early-stage bowel cancer, including through a blood test.
- Discovering potential new treatments for bowel cancer.
- Matching people with bowel cancer to the best treatment for their disease.
What is bowel cancer?
Bowel cancer begins as an uncontrolled growth of cells in the walls of the bowel (the large intestine – the colon or the rectum). If untreated, the cancer can spread to other organs. Bowel cancer may also be called colon cancer or colorectal cancer.
Most bowel cancers arise from cells in the bowel lining called epithelial cells. These cells become cancerous after acquiring genetic changes that make them divide excessively and become long-lived.
Small non-cancerous growths in the bowel lining called ‘polyps’ often precede bowel cancer. Most polyps do not grow any further. Occasionally the cells in a polyp undergo changes that make them grow into a larger tumour. This can damage or block the bowel. ‘Metastatic’ or ‘secondary’ bowel cancer occurs when cancer cells spread beyond the bowel and travel to other parts of the body, where they grow as tumours.
Bowel development and cancer
Bowel cancers arise from the cells that line the bowel. They occur because the systems that normally control cell growth and survival have stopped working properly. Many processes that occur in bowel cancer cells are similar to those occurring during the development and growth of the bowel in embryos. Understanding how cell growth is controlled during bowel development is revealing what goes awry in bowel cancer.
Bowel cancer risk factors
Most bowel cancers arise ‘spontaneously’, with no predictable cause. Like many cancers, the risk of developing bowel cancer increases with age. About 92 per cent of people diagnosed with bowel cancer are over the age of 50.
Other risk factors for developing bowel cancer are:
- A history of developing polyps, or an earlier case of bowel, stomach or uterine cancer. These cancers may all be caused by similar cancer-causing gene abnormalities.
- Having relatives who had polyps or bowel cancer. People can be tested for inherited (familial) bowel cancer risk genes.
- Having inflammatory bowel disease, such as colitis or Crohn’s disease.
- A diet high in red meats, processed meats, fried foods or alcohol, or low in vegetables, fruit and whole grains.
- Being obese or physically inactive.
- Smoking.
How is bowel cancer detected?
The earliest, most treatable forms of bowel cancer generally have no symptoms. Clinical trials have shown that offering bowel cancer screening tests to people older than 50 years saves lives through early detection. Screening is a cost-effective way to detect bowel cancer at early and curable stages.
Currently, bowel cancer screening uses the faecal occult blood test (FOBT) that detects small amounts of blood in a stool (faeces) sample. Blood in stools is a possible sign of early bowel cancer.
When bowel cancer is suspected, the bowel lining can be examined by colonoscopy or sigmoidoscopy. In these, a flexible video camera is passed into the bowel through the anus. Samples from possible bowel cancer can be removed for microscopic diagnosis.
Some bowel cancers can also be detected using non-invasive imaging techniques such as ‘virtual colonoscopy’ or a magnetic resonance imaging (MRI) scan to create a three-dimensional image of the bowel. These techniques can miss polyps or small cancers that may be detected by colonoscopy and are currently considered inferior to a colonoscopy.
There is as yet no blood test that can reliably detect bowel cancer. Developing such a test is a goal of our bowel cancer researchers
For further information about bowel cancer detection please visit Bowel Cancer Australia.
How is bowel cancer treated?
Earlier diagnosis and better treatments have seen a doubling in survival rates from bowel cancer in Australia over the past 40 years.
When bowel cancer is detected early, before it has spread outside the bowel, it can often be cured by using surgery to remove the section of the bowel that contains the cancer.
When the cancer has spread outside the bowel (metastatic bowel cancer), surgery is usually combined with other treatments to kill any remaining cancer cells. Chemotherapy is an important part of treatment for metastatic bowel cancer. Several different chemotherapy drugs are used to treat bowel cancer, either alone or in combinations of two or more drugs.
Recently, some ‘monoclonal antibody’ treatments have been shown to be effective for treating bowel cancer. These contain antibodies that bind to proteins that are helping the bowel cancer to grow. This blocks the proteins’ function, preventing cancer growth. Monoclonal antibody treatments are sometimes combined with chemotherapy to increase their effect.
Bowel cancer treatment is currently hindered by a poor understanding of which patients will respond to which treatments. Genetic testing of bowel cancers is starting to reveal certain gene changes that predict whether a patient will respond well to a certain type of treatment. In particular, this testing can indicate whether monoclonal antibody treatments will be effective.
For more detailed information about bowel cancer treatment, please visit Bowel Cancer Australia.
WEHI researchers are not able to provide specific medical advice specific to individuals. If you have bowel cancer and wish to find out more information about clinical trials, please visit Australian Cancer Trials or the Australian New Zealand Clinical Trials Registry, or consult your medical specialist.
Researchers:
Super Content:
Clinician scientists Associate Professor Jeanne Tie and Associate Professor Sumitra Ananda are leading trials of a blood test to guide cancer treatment after surgery.
Our research into bowel development has suggested a new mechanism for how bowel cancer starts.
A collaborative research effort has offered new hope for treating bowel cancer.
Dr Tracy Putoczki speaks with ABC Radio AM about her team's discovery of a new target for anti cancer therapies
Our research has demonstrated a potential new way to treat two of the most common cancers worldwide.